TP53 and diffuse large B-cell lymphoma: However, for the DLBCL lines we tested, both venetoclax-sensitive and -resistant lines had TP53 mutations, suggesting that TP53 mutations may not be a significant venetoclax resistance mechanism in DLBCL, but this would need further testing.